ASCO GU 2022 Highlights

Combining the PARP inhibitor olaparib (Lynparza) with abir­aterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial, presented at the 2022 ASCO Genitourinary Cancers Symposium. Read More ›

Adjuvant pembrolizumab (Keytruda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 ASCO Genitourinary Cancers Symposium. Read More ›

The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial. Read More ›

Treatment with the androgen receptor inhibitor darolutamide (Nubeqa), in combination with androgen-deprivation therapy (ADT) and docetaxel, significantly improved overall survival (OS) compared with ADT and docetaxel alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to recent results from the phase 3 ARASENS clinical trial, which were simultaneously published in the New England Journal of Medicine. Read More ›

The neoadjuvant combination of avelumab (Bavencio) and axitinib (Inlyta) resulted in a partial response (PR) rate of 30% in patients with localized renal-cell carcinoma (RCC) at high risk for relapse after nephrectomy, according to results from the phase 2 NeoAvAx clinical trial. Read More ›

Continuous enzalutamide (Xtandi) treatment in combination with docetaxel significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer who had disease progression on enzalutamide alone, according to results from the phase 3b PRESIDE clinical trial. Read More ›

Neoadjuvant enfortumab vedotin (Padcev) showed promising antitumor activity in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for cisplatin therapy, according to preliminary findings from cohort H of the phase 1b/2 EV-103 clinical trial. Read More ›

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: